Skip to main content

Table 1 Clinicopathologic characteristics of all patients with metastatic endometrial carcinoma treated with neoadjuvant chemotherapy

From: Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study

Characteristics Total (n = 32, %)
Age at diagnosis, years
  Median (range) 56 (34–77)
Menopausal status
  Premenopause 9 (28.1)
  Postmenopause 23 (71.9)
Histologic subtype
  Endometrioid 18 (56.3)
  Serous 5 (15.6)
  Clear cell 1 (3.1)
  Carcinosarcoma 6 (18.8)
  Others 2 (6.3)
Grade
  Low 11 (34.3)
  High 7 (21.9)
  Not applicable 14 (43.8)
FIGO stage
  IIIC 4 (12.5)
  IVB 28 (87.5)
CA-125 at diagnosis, IU/ml
  Median (range) 192.7 (8.6–3489.0)
CA-125 after NAC, IU/ml
  Median (range) 20.2 (7.0–1490.0)
NAC regimen
  Paclitaxel-carboplatin 25 (78.1)
  Doxorubicin-cisplatin 2 (6.3)
  Paclitaxel-cisplatin-bevacizumab 2 (6.3)
  Ifosfamide-cisplatin 2 (6.3)
  Etoposide-cisplatin 1 (3.1)
Number of NAC cycles
  Median (range) 6 (2–12)
  2–3 11 (34.4)
  4–6 10 (31.2)
  ≥7 11 (34.4)
Response to NAC
  CR 2 (6.3)
  PR 24 (75.0)
  SD 4 (12.5)
  PD 2 (6.3)
Residual tumor after IDS
  No gross residual 23 (71.9)
  < 1 cm 7 (21.9)
  ≥ 1 cm 2 (6.2)
  1. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, NAC Neoadjuvant chemotherapy, IDS Interval debulking surgery, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease